Myelodysplastic Syndrome Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals,

Myelodysplastic Syndrome Pipeline constitutes 120+ key companies continuously working towards developing 125+ Myelodysplastic Syndrome treatment therapies, analyzes DelveInsight.

Myelodysplastic Syndrome Overview:

Myelodysplastic syndrome (MDS) is a diverse group of blood-related cancers characterized as clonal disorders of hematopoietic stem cells, resulting in abnormal cell development (dysplasia) and ineffective blood cell production in the bone marrow. In some cases, MDS can progress to acute myeloid leukemia (AML). The condition is most frequently diagnosed in individuals over 65 years of age and presents with low levels of red blood cells, white blood cells, and platelets. The progression and symptoms of the disease can vary significantly among patients.

MDS can develop due to several factors, including environmental exposures (e.g., benzene, radiation), prior chemotherapy, or idiopathic causes, which are more common in older adults. Certain inherited or acquired bone marrow failure syndromes, such as Fanconi anemia and acquired aplastic anemia, can increase the risk of MDS or present with similar features.

MDS may arise spontaneously (de novo) or as a consequence of other conditions or treatments, known as treatment-related MDS. Drugs such as alkylating agents or topoisomerase II inhibitors have been linked to MDS development, typically appearing 2 to 7 years after treatment. The disease often involves genetic and chromosomal abnormalities, either present from the start or developing due to the aforementioned factors. These abnormalities are found in over 80% of patients and may include chromosome translocations or aneuploidy (gain or loss of chromosomes).

Download our report @ https://www.delveinsight.com/report-store/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Myelodysplastic Syndrome Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Myelodysplastic Syndrome Therapeutics Market.

Key Takeaways from the Myelodysplastic Syndrome Pipeline Report

DelveInsight's Myelodysplastic Syndrome pipeline report depicts a robust space with 120+ active players working to develop 125+ pipeline therapies for Myelodysplastic Syndrome treatment.
In June 2024, the FDA approved imetelstat (Rytelo) for adults with low- to intermediate-1 risk MDS who have transfusion-dependent anemia requiring four or more red blood cell units over eight weeks and who have not responded to or are ineligible for erythropoiesis-stimulating agents. ​
Key Myelodysplastic Syndrome companies such as Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others are evaluating new drugs for Myelodysplastic Syndrome to improve the treatment landscape.
Promising Myelodysplastic Syndrome pipeline therapies in various stages of development include Tamibarotene, CA-4948, RVU120, MNV-201, and others.

Myelodysplastic Syndrome Pipeline Analysis
The Myelodysplastic Syndrome pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Myelodysplastic Syndrome Market.

Categorizes Myelodysplastic Syndrome therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Myelodysplastic Syndrome drugs under development based on:

Stage of development

Myelodysplastic Syndrome Route of administration

Target receptor

Monotherapy vs. combination therapy

Myelodysplastic Syndrome Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Myelodysplastic Syndrome Licensing agreements

Funding and investment activities supporting future Myelodysplastic Syndrome market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Myelodysplastic Syndrome Emerging Drugs

Tamibarotene: Syros Pharmaceuticals
CA-4948: Curis
RVU120: Ryvu Therapeutics
MNV-201: Minovia Therapeutics

Myelodysplastic Syndrome Companies

There are over 120 notable companies currently engaged in developing treatments for Myelodysplastic Syndrome (MDS). Among these, Syros Pharmaceuticals has a drug candidate that is in the most advanced stage of development-Phase III clinical trials.

DelveInsight's report covers around 125+ products under different phases of Myelodysplastic Syndrome clinical trials like

Myelodysplastic Syndrome Late stage Therapies (Phase III)
Myelodysplastic Syndrome Mid-stage Therapies (Phase II)
Myelodysplastic Syndrome Early-stage Therapies (Phase I)
Myelodysplastic Syndrome Pre-clinical and Myelodysplastic Syndrome Discovery stage Therapies
Myelodysplastic Syndrome Discontinued & Inactive Therapies

Myelodysplastic Syndrome pipeline report provides the Myelodysplastic Syndrome therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Myelodysplastic Syndrome Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Myelodysplastic Syndrome Therapies and Key Myelodysplastic Syndrome Companies: Myelodysplastic Syndrome Clinical Trials and recent advancements https://www.delveinsight.com/report-store/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Myelodysplastic Syndrome Pipeline Therapeutic Assessment
• Myelodysplastic Syndrome Assessment by Product Type
• Myelodysplastic Syndrome By Stage
• Myelodysplastic Syndrome Assessment by Route of Administration
• Myelodysplastic Syndrome Assessment by Molecule Type

Download Myelodysplastic Syndrome Sample report to know in detail about the Myelodysplastic Syndrome treatment market @ Myelodysplastic Syndrome Therapeutic Assessment https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Myelodysplastic Syndrome Current Treatment Patterns
4. Myelodysplastic Syndrome - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Myelodysplastic Syndrome Late-Stage Products (Phase-III)
7. Myelodysplastic Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Myelodysplastic Syndrome Discontinued Products
13. Myelodysplastic Syndrome Product Profiles
14. Myelodysplastic Syndrome Key Companies
15. Myelodysplastic Syndrome Key Products
16. Dormant and Discontinued Products
17. Myelodysplastic Syndrome Unmet Needs
18. Myelodysplastic Syndrome Future Perspectives
19. Myelodysplastic Syndrome Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Myelodysplastic Syndrome Pipeline Reports Offerings: https://www.delveinsight.com/report-store/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.